IP Library Granted Patent US 9,622,459
Granted Patent B2
US 9,622,459 · App. 13/951,996 · Granted Apr 18, 2017

Humanized light chain mice

Inventors: Lynn Macdonald (White Plains, NY); Cagan Gurer (Valhalla, NY); Karolina A. Meagher (Tarrytown, NY); Sean Stevens (San Francisco, CA); Andrew J. Murphy (Croton-on-Hudson, NY)
Assignee: REGENERON PHARMACEUTICALS, INC.
A01K67/0278C07K16/2866C07K16/462C12N9/6489A01K2217/072A01K2217/15A01K2227/105A01K2267/01C12N2800/204C12N2800/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,622,459
App. No.
13/951,996
Granted
Apr 18, 2017
Kind
B2
Abstract

Non-human animals, tissues, cells, and genetic material are provided that comprise a modification of an endogenous non-human heavy chain immunoglobulin sequence and that comprise an ADAM6 activity functional in a mouse, wherein the non-human animals express a human immunoglobulin heavy chain variable domain and a cognate human immunoglobulin λ light chain variable domain.

Claims (28)

1. A method for making an antibody that binds to an antigen of interest, wherein the method comprises:

(a) exposing a mouse to an antigen of interest,

(b) isolating one or more B lymphocytes of the mouse, wherein the one or more B lymphocytes express an antibody that binds the antigen of interest, wherein the expressed antibody that binds the antigen of interest includes an immunoglobulin light chain comprising a human immunoglobulin λ light chain variable domain and a mouse immunoglobulin light chain constant domain, and comprises an immunoglobulin heavy chain comprising a human immunoglobulin heavy chain variable domain and a mouse immunoglobulin heavy chain constant domain,

(c) identifying a nucleic acid sequence that encodes the human immunoglobulin λ light chain variable domain of the antibody that binds the antigen of interest, and

(d) employing the nucleic acid sequence of (c) with a human immunoglobulin light chain constant region nucleic acid sequence to make a human immunoglobulin light chain for the antibody that binds the antigen of interest;

wherein the mouse comprises

(i) an insertion of one or more human Vλ gene segments and one or more human Jλ gene segments upstream of a mouse immunoglobulin light chain constant region gene, wherein the one or more human Vλ gene segments and one or more human Jλ gene segments are operably linked to the mouse immunoglobulin light chain constant region gene,

(ii) an insertion of one or more human V H gene segments, one or more human D H gene segments and one or more human J H gene segments upstream of a mouse immunoglobulin heavy chain constant region gene, wherein the one or more human V H gene segments, one or more human D H gene segments and one or more human J H gene segments are operably linked to the mouse immunoglobulin heavy chain constant region gene, and

(iii) an ectopic nucleotide sequence that encodes an ADAM6 protein or a functional fragment thereof.

2. The method of claim 1 , wherein the mouse immunoglobulin light chain constant region gene of (i) is a mouse Cκ.

3. The method of claim 1 , wherein the mouse immunoglobulin light chain constant region gene of (i) is a mouse Cλ.

4. The method of claim 3 , wherein the mouse Cλ is a mouse Cλ2.

5. The method of claim 3 , wherein the mouse Cλ is at least 90% identical to mouse Cλ2.

6. The method of claim 1 , wherein the mouse comprises an insertion of at least 12 human Vλ gene segments and at least one human Jλ gene segment upstream of the mouse immunoglobulin light chain constant region gene.

7. The method of claim 1 , wherein the mouse comprises an insertion of at least 28 human Vλ gene segments and at least one human Jλ gene segment upstream of the mouse immunoglobulin light chain constant region gene.

8. The method of claim 1 , wherein the mouse comprises an insertion of at least 40 human Vλ gene segments and at least one human Jλ gene segment upstream of the mouse immunoglobulin light chain constant region gene.

9. The method of claim 1 , wherein the ectopic nucleotide sequence is present at the immunoglobulin heavy chain locus of the mouse.

10. The method of claim 9 , wherein the ectopic nucleotide sequence is positioned within the variable region of the human immunoglobulin heavy chain locus.

11. The method of claim 10 , wherein the ectopic nucleotide sequence is positioned between two human V H gene segments.

12. The method of claim 1 , wherein the ectopic nucleotide sequence is present at a position other than the immunoglobulin heavy chain locus of the mouse.

13. The method of claim 10 , wherein the ectopic nucleotide sequence is positioned between a V H gene segment and a D H gene segment.

14. The method of claim 1 , wherein the mouse further comprises a human Vκ-Jκ intergenic region from a human κ light chain locus, wherein the human Vκ-Jκ intergenic region is contiguous with the one or more human Vκ gene segments and one or more human Jκ gene segments.

15. The method of claim 14 , wherein the human Vκ-Jκ intergenic region is placed between a human Vκ gene segment and a human Jκ gene segment.

16. The method of claim 14 , wherein the human Vκ-Jκ intergenic region comprises SEQ ID NO: 158.

17. The method of claim 1 , wherein the nucleic acid sequence of step (c) is isolated from a hybridoma made from the B cell of step (b).

18. The method of claim 3 , wherein the mouse Cλ is at least 95% identical to mouse Cλ2.

19. The method of claim 3 , wherein the mouse Cλ is at least 97% identical to mouse Cλ2.

20. The method of claim 3 , wherein the mouse Cλ is at least 98% identical to mouse Cλ2.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 29, 2013
From: MACDONALD, LYNN; GURER, CAGAN; HOSIAWA, KAROLINA A.; STEVENS, SEAN; MURPHY, ANDREW J.
To: REGENERON PHARMACEUTICALS, INC.
Reel/Frame 030895/0339 →
Continuity (3)
Division 13716238 · Dec 17, 2012
Provisional Application 61578097 · Dec 20, 2011
Related Publication 20140017228A1 · Jan 16, 2014